

ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Company name- **Biond Biologics** - * Website - <https://www.biondbio.com> *

CEO name- Tehila Ben-Moshe -*

CATEGORY: **Biotech/Pharma** *

SESSIONS

Redefining Cancer Care: Novel Therapeutic Modalities and Targets Shaping the Future

o Executive Summary / Investment Rational Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths.

Biond Biologics is an Israeli, private, clinical-stage biotech company, developing innovative cancer therapies.

Our Immuno-Oncology pipeline includes:

- **BND-67: an agent that blocks CD28 shedding, Phase 1 in Q2 2026**
- **BND-35: ILT3 antagonist antibody, phase 1 started at Q2/2024**
- **BND-22: ILT2 antagonist antibody, licensed to Sanofi for \$125 million upfront payment, and up to \$1 billion in milestones and royalties, Phase 2.**

In addition, we are developing our pioneering INspire platform, for intracellular delivery of payloads, specifically to tumor cells. Using INspire we have been able to demonstrate killing of tumor cells in vivo in various mice models.

o Core Technology What is the technology, its uniqueness, and its value proposition?

The company discovered a novel regulatory mechanism that involves the shedding of CD28 receptor, a key co-stimulatory pathway in T cells. CD28-shedding was found to attenuate T cells cytotoxic activity and to effectively constitute a resistant setting to current immunotherapies for cancer indications. BND-67 is a first in class agent that can selectively and efficiently block CD28-shedding. In pre-clinical *in-vivo* models, BND-67 was able to reverse immunotherapy resistant cases and showed a prominent effect on the differentiation and activation status of T cells.

o Product Profile/Pipeline Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.

BND-67 is currently in IND-enabling studies stage and expected to enter FIH clinical trial towards of Q2 2026.

o Business Strategy Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.

Biond launched a Phase I dose-escalation clinical trial for BND-35, as a monotherapy and in combination therapy will be initiated in H2 2025. Additionally, Biond is advancing the preclinical development of BND-67 toward clinical trials. The company is open to exploring various commercial collaboration opportunities with potential partners.

o What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans

Biond is actively seeking to expand its pipeline with additional programs in oncology and immunology